[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Baptist Health South Florida\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":436},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,40,65,90,119,141,165,190,216,239,263,286,313,337,364,388,411],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100642619","effect-of-ie-glasses-on-mri-patient-outcomes-100642619",false,"NCT07660952","Effect of IE Glasses on MRI Patient Outcomes","Examining the Effect of Immersive Entertainment Glasses on Magnetic Resonance Imaging-related Patient Outcomes","Inclusion Criteria:\n\n* Adult patients at least 18 years of age\n* Outpatients\u002Finpatients scheduled for an MRI with anesthesia\n* Inpatients scheduled for an MRI with an IV\u002FPO sedative\n\nExclusion Criteria:\n\n* Pregnant patients","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"NA","Examine the effect of immersive entertainment glasses (IEG) on patients' claustrophobia-associated anxiety levels during magnetic resonance imaging (MRI).",[26,27],"MRI-related Anxiety","MRI Completion Rate","NOT_YET_RECRUITING","2026-06-16",{"date":31,"type":32},"2026-06-22","ACTUAL",{"date":34,"type":20},"2026-07-01",{"date":36,"type":20},"2027-07-01",{"name":38,"class":39},"Baptist Health South Florida","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100172879","evaluation-of-branch-endografts-in-the-treatment-of-aortic-aneurysms-100172879","NCT01524211","Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms","Zenith t-Branch Eligibility Criteria:\n\nInclusion Criteria\n\nThe patient must have one of the following:\n\n1. Degenerative, atherosclerotic thoracoabdominal, suprarenal and juxtarenal aortic aneurysms (fusiform or saccular):≥55mm in diameter in a male or ≥50mm in diameter in a female, or\n2. Thoracoabdominal aortic aneurysm with a history of growth ≥0.5 cm per year, or\n3. Penetrating ulcers: ≥20mm in depth or\n4. Chronic type B aortic dissections: ≥50mm total aortic diameter or\n5. Symptomatic pathology (aneurysm, ulcer or chronic dissection) of any size.\n\nAdditional criteria for LP material\n\n• Iliofemoral access vessels \\\u003C8mm or with significant atherosclerotic occlusive disease that would require an iliac conduit as determined by the Principle Investigator\n\nExclusion Criteria\n\nGeneral Criteria\n\n1. Life-expectancy less than 12 months\n2. Refusal to receive blood products\n3. Age \\\u003C18 years\n4. Pregnant or breastfeeding or planning on becoming pregnant within 60 months\n5. Unwilling to comply with the follow-up schedule\n6. Inability or refusal to give informed consent by subject and\u002For Legally Authorized Representative (LAR); should one be utilized\n\nMedical Criteria\n\n1. Uncontrolled systemic infection\n2. Untreatable malignancy\n3. Uncontrollable anaphylaxis to iodinated contrast\n4. Known allergy(ies) to device materials\n\nAnatomic Criteria\n\n1. Any pathology of mycotic origin\n2. Aortic fistulous communication with non-vascular structure (e.g. esophagus, bronchial)\n3. Inability to insert the Zenith® t-Branch device through iliofemoral approach\n4. Proximal and distal neck angle less than 90 degrees relative to the long axis of the aneurysm\n5. Proximal landing zone length \\\u003C25mm to allow secure fixation and seal\n6. Proximal landing zone diameter of \\\u003C24mm or \\>42mm\n7. Distal landing zone length \\\u003C25mm in the abdominal aorta or \\\u003C20mm in the iliac arteries\n8. Distal landing zone diameter of \\\u003C14mm or \\>30mm in the abdominal aorta, or \\\u003C7mm or \\>28mm in the iliac arteries\n\nTerumo Arch Branch Eligibility Criteria\n\nInclusion Criteria\n\nThe subject must have one of the following:\n\n1. Degenerative, atherosclerotic aneurysm involving the ascending aorta, aortic arch or proximal descending aorta ≥55 mm in diameter or \\> 50 mm with a history of growth ≥5 mm in the last 6 months, or\n2. Penetrating ulcers: ≥20 mm in depth, or\n3. Chronic aortic dissections: ≥50mm total aortic diameter. AND Prohibitive or high-risk for standard open surgical repair, defined as having one or more of the following pre-existing conditions.\n\n   1. Age \\>85 years old.\n   2. Prior median sternotomy (for any reason).\n   3. Prior open or endovascular thoracic aortic repair.\n   4. Severe aortic calcification.\n   5. Severe occlusive disease of one or more arch vessels.\n   6. Moderate-severe COPD (FEV1 \\\u003C80% predicted).\n   7. Severe CKD (Stage 3 or greater, eGFR \\\u003C60 mL\u002Fmin).\n   8. LV dysfunction.\n   9. Chronic steroid or immunosuppressive use.\n   10. History of increased risk of bleeding.\n   11. Neurocognitive deficits that may significantly impact postoperative rehabilitation.\n   12. Musculoskeletal conditions that may significantly impact postoperative rehabilitation.\n\nExclusion Criteria\n\nGeneral Criteria\n\n1. Life expectancy \\\u003C1 year.\n2. Refusal to receive blood products.\n3. Age \\\u003C18 years.\n4. Pregnant, breastfeeding, or planning to become pregnant within 60 months.\n5. Unwilling to comply with the follow-up schedule.\n6. Inability or refusal to give informed consent by subject and\u002For Legally Authorized Representative (LAR); should one be utilized.\n7. Willingness to travel, if needed, to participate in a manufacturer-sponsored clinical trial at another institution.\n\nMedical Criteria\n\n1. Pending cardiac surgery.\n2. Untreatable severe, symptomatic coronary or valvular disease.\n3. Prior mechanical aortic valve replacement (not bioprosthetic).\n4. History of TAVR (Transcatheter Aortic Valve Replacement)\n5. Severe, calcific aortic valvular stenosis.\n6. Uncontrolled systemic infection.\n7. Untreatable malignancy with \\\u003C1 year expected survival.\n8. Uncontrollable anaphylaxis to iodinated contrast.\n9. Known allergy(ies) to device materials. (i.e. polyester, nitinol).\n\nAnatomic Criteria\n\n1. Any pathology of mycotic origin.\n2. Aortic fistulous communication with non-vascular structure (e.g. esophagus, bronchial).\n3. Acute (\\\u003C2 weeks) aortic dissection.\n4. Type A dissection.\n5. Symptomatic or ruptured pathology.\n6. Anatomy suitable for repair using commercially-available endograft.\n7. Inability to insert the Arch Branch endograft through an iliofemoral approach.\n8. Untreated, known extracranial carotid stenosis \\>80%.\n9. Ascending aortic angulation with radius of curvature \\\u003C15mm in the intended landing zone.\n10. Proximal aortic landing zone length \\\u003C25 mm.\n11. Proximal aortic landing zone diameter of \\>43mm or \\\u003C28 mm.\n12. Distal aortic landing zone diameter \\\u003C20 mm.\n13. Total length along the outer curve from the distal coronary to the proximal edge of the brachiocephalic trunk \\\u003C70mm.\n14. Target arch vessels:\n15. Distal branch landing zone dimensions: I. Brachiocephalic trunk (innominate artery, BCT): Diameter \\>24 mm or \\\u003C6 mm, length \\\u003C15 mm. ii. Common carotid artery: Diameter \\\u003C6 mm, length \\\u003C25mm. iii. Subclavian artery: Diameter \\\u003C6 mm, length \\\u003C25mm.",{"count":47,"type":20},235,[23],"Zenith t-Branch Study Cohort: The purpose of this study is to collect information on the Cook Zenith t-Branch endovascular stent-graft system and the Terumo Arch Branch for the treatment of aortic aneurysms.\n\nTerumo Arch Branch Study Cohort: The purpose of this additional study arm to the current IDE clinical trial is to collect a priori information on the Terumo Arch Branch Endograft for the treatment of proximal thoracic aortic pathologies that cannot be treated with conventional thoracic endografts.",[51,52],"Thoracoabdominal Aortic Aneurysm","Aortic Arch Aneurysm",[54],"Aortic Aneurysms","RECRUITING","2026-06-12",{"date":58,"type":32},"2026-06-15",{"date":60,"type":32},"2012-01-25",{"date":62,"type":20},"2032-01",{"name":38,"class":39},1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100546639","proton-pulsed-reduced-dose-rate-radiotherapy-for-recurrent-cns-malignancies-trial-100546639","NCT06397560","PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial","PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies (POPCORN) Trial","POPCORN","Inclusion Criteria:\n\n* Karnofsky performance status ≥ 50\n* Histologically-confirmed or radiographic evidence of recurrent \u002F progressive glioma\n* Prior treatment with radiotherapy to a minimum dose of 45 Gy\n* At least 6 months or greater between completion of prior radiotherapy and enrollment in this study. If prospective participants have not passed an interval of at least 6 months, they may still be eligible if they meet one or more of the following criteria:\n\n  1. New areas of tumor outside the original radiotherapy fields as determined by the investigator.\n  2. Histologic confirmation of tumor through biopsy or resection AND an interval of at least 90 days between completion of radiotherapy and enrollment.\n  3. Nuclear medicine imaging, magnetic resonance (MR) spectroscopy, or MR perfusion imaging consistent with true progressive disease, rather than radiation necrosis obtained within 28 days of enrollment AND an interval of at least 90 days between completion of radiotherapy and enrollment.\n* Must have recovered from grade 3+ toxicities of prior therapy and there must be a minimum time of 28 days prior to enrollment from the administration of any investigational agent or prior cytotoxic therapy\n* Must not be pregnant (positive pregnancy test) or breastfeeding. Must agree to use of highly effective contraception during radiotherapy treatment and for an additional 6 months. Should a participant become pregnant or suspect that they are pregnant while participating in this study, they should notify the treating physician immediately.\n\nHighly effective and acceptable forms of contraception are:\n\n* Male condom plus spermicide\n* Cap plus spermicide\n* Diaphragm plus spermicide\n* Copper T\n* Progesterone T\n* Levonorgestrel-releasing intrauterine system (e.g., Mirena®)\n* Implants\n* Hormone shot or injection\n* Combined pill\n* Mini-pill\n* Patch\n\nIndividuals who meet any of the following criteria will not need contraception:\n\n* Individuals assigned male at birth\n* Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments\n* Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the postmenopausal range for individuals under 50\n* Radiation-induced oophorectomy with last menses \\> 1 year ago\n* Chemotherapy-induced menopause with \\>1 year interval since last menses\n* Surgical sterilization (bilateral oophorectomy or hysterectomy)\n\nExclusion Criteria:\n\n* Two or more courses of prior radiotherapy\n* Inability to undergo an MRI with contrast\n* Leptomeningeal evidence of recurrent disease\n* Multi-focal disease\n* Any other condition that may put a participant at higher risk, at the discretion of the investigator.",{"count":74,"type":20},28,[23],"The purpose of this research study is to see if a specific type of radiation therapy, called \"proton pulsed reduced dose rate\" or \"PRDR radiotherapy\" has any benefits at dose levels and number of fractions thought to be acceptable in earlier research studies. The researchers want to find out what effects (good and bad) PRDR has on people with cancer in the brain called a \"recurrent high-grade glioma\" meaning that it grows fast, can spread quickly, and it has come back or gotten worse after being treated previously.",[78,79,80],"Glioma","Glioma, Malignant","Recurrent Glioma","2026-05-28",{"date":83,"type":32},"2026-06-01",{"date":85,"type":32},"2025-04-30",{"date":87,"type":20},"2029-06",{"name":38,"class":39},2,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":64},"100519787","phase-1-18f-fluciclovine-pet-amino-acid-evaluation-of-brain-metastasis-treated-with-stereotactic-radiosurgery-100519787","NCT06048094","18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery","18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery (FACILITATE)","FACILITATE","Inclusion Criteria:\n\n* Diagnosis of cancer with radiographic finding of brain metastasis\n* Any number of brain metastasis, with all lesions ≤ 2 cm in maximum dimension\n* Planned treatment with SRS as per the treating physician team\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Individuals of reproductive potential need to employ two highly effective and acceptable forms of contraception for at least 4 weeks prior to screening and agree to use such a method during study participation up to an additional 1 week following the last 18F-fluciclovine PET\n\nExclusion Criteria:\n\n* Prior anaphylactic reaction to 18F-fluciclovine\n* Radiographic evidence of leptomeningeal disease\n* Prior whole-brain radiation therapy\n* Inability to undergo MRI (e.g., due to safety reasons, such as presence of a pacemaker)\n* Pregnant or positive serum pregnancy test within 14 days of registration\n* Individuals expecting to be breastfeeding at the time of 18F-fluciclovine and unwilling to stop breast-feeding for 24 hours. Temporary cessation of breastfeeding for 24 hours after the time of imaging is allowed.\n* Major medical illness or psychiatric\u002Fcognitive impairments, which in the investigator's opinion, will prevent completion of protocol and\u002For preclude informed consent\\*\n\n  * A legally authorized representative (LAR) may consent on a potential participant's behalf in the case of cognitive impairment, if in the investigator's opinion, that impairment would not prevent completion of the protocol.",{"count":99,"type":20},46,[101],"PHASE1","This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis after SRS.",[104,105,106],"Brain Metastases","Brain Metastases, Adult","Brain Cancer",[108,109,110],"stereotactic radiosurgery","18F-flucicloivine","PET imaging","2026-05-18",{"date":113,"type":32},"2026-05-20",{"date":115,"type":32},"2024-04-11",{"date":117,"type":20},"2033-05",{"name":38,"class":39},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":64},"100478031","integration-of-neurocognitive-biomarkers-into-a-neuro-oncology-clinic-100478031","NCT05504681","Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic","Inclusion Criteria:\n\n1. All adult (18+) patients with central nervous system (CNS) tumors, both primary brain malignancies and brain metastases, treated with radiotherapy (partial brain, stereotactic radiosurgery, stereotactic fractionated radiotherapy, or whole-brain radiotherapy), surgery, and\u002For antineoplastic therapy and followed thereafter at Miami Cancer Institute (MCI)\n2. Life expectancy ≥ 6 months\n3. Willingness to participate in ongoing registration study\n\nExclusion Criteria:\n\n1. Patients receiving radiotherapy to the brain for functional disease (arteriovenous malformations, trigeminal neuralgia, essential tremors, etc.)\n2. Pediatric patients (\\\u003C18 years old), pregnant women, and prisoners.",{"count":126,"type":20},200,"OBSERVATIONAL","This is prospective observational registry study that will assess 1) if the neurocognitive function app (Brainlab Cognition) can be used in a widespread neuro-oncology clinic setting and 2) if patient reported quality of life parameters can be obtained electronically and integrated into clinic.",[130],"Neurocognitive Disorders",[132,133],"Neurocognitive","Brainlab Cognition app",{"date":135,"type":32},"2026-05-19",{"date":137,"type":32},"2021-11-30",{"date":139,"type":20},"2032-04",{"name":38,"class":39},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":148,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":64},"100627997","phase-2-assessing-efficacy-of-neoadjuvant-adt-in-localized-high-risk-prostate-cancer-patients-utilizing-18f-flotufolastat-psma-petct-100627997","NCT07455903","Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET\u002FCT","Assessing the Efficacy of Neoadjuvant Androgen Deprivation Therapy (ADT) Utilizing 18F-Flotufolastat PSMA PET\u002FCT in Patients With High-Risk Localized Prostate Cancer (LHRPC)","Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study.\n* Males aged ≥18 years.\n* ECOG performance status ≤ 1\n* Histologically confirmed adenocarcinoma of the prostate in a patient amenable to radical prostatectomy\n* Pathologically proven prostate adenocarcinoma with ≥ 1 High-risk feature based on NCCN guidelines.\n\n  1. cT3-cT4\n  2. International Society of Urological Pathology (ISUP) Grade group 4 (Gleason score 8) or grade group 5 (Gleason score 9-10)\n  3. PSA \\>20 ng\u002FmL\n* Clinically negative lymph nodes as established by PSMA PET\u002FCT imaging. Patients who are node positive by PSMA PET\u002FCT (e.g., N1), but whose nodes do not meet traditional size criteria for positivity (e.g., they measure ≥ 10mm on either the CT or MRI portion of the PET or on a dedicated CT or MRI) will not be considered N1 and would be eligible for this study.\n* Patient is willing to use barrier-method of contraception along with another effective contraceptive method if engaged in sexual activity with a pregnant person or individual of childbearing potential (until 1 week after completing 18F-flotufolastat PSMA PET\u002FCT Scans.\n* Clinical laboratory values during screening:\n\n  1. Hemoglobin ≥ 10.0 g\u002FdL\n  2. Absolute neutrophil count (ANC) ≥ 1.8 × 10⁹\u002FL\n  3. Platelets ≥ 100 × 10⁹\u002FL\n\nExclusion Criteria:\n\n* Known allergies, hypersensitivity, or intolerance to 18F-flotufolastat.\n* Unable to receive androgen deprivation therapy.\n* Prostate cancer with significant neuroendocrine or other rare variant pathology\n* Evidence of metastatic disease involving bone, viscera, or lymph nodes superior to the bifurcation of the common iliac arteries on PSMA PET\u002FCT\n* Renal impairment (glomerular filtration rate \\\u003C30 mL\u002Fmin)\n* History of prior radiation therapy for prostate cancer\n* Any of the following within 6 months prior to the first dose of study treatment: severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, clinically significant ventricular arrhythmias, or New York Heart Association Class II to IV heart disease.\n* Uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or untreated HIV infection.\n* Other malignancies other than prostate cancer in the past 5 years\n\n  a. Cured basal cell or squamous cell skin cancers can be enrolled.\n* Severe or uncontrolled concurrent infections are not eligible.\n* Treated with concomitant cytotoxic cancer therapy for any other primary site.\n* Patients who are unable to complete the study requirements of 2nd PSMA imaging or surgery for the primary endpoints.\n* Any condition that, in the opinion of the investigator, would preclude participation in this study.","MALE",{"count":150,"type":20},50,[152],"PHASE2","The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).",[155,156],"Prostate Cancer","Localized Prostate Carcinoma","2026-05-12",{"date":159,"type":32},"2026-05-13",{"date":161,"type":32},"2026-04-23",{"date":163,"type":20},"2030-10",{"name":38,"class":39},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},"100471909","phase-2-cabozantinib-for-patients-with-recurrent-or-progressive-meningioma-100471909","NCT05425004","Cabozantinib for Patients With Recurrent or Progressive Meningioma","A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma","Inclusion Criteria\n\n1. Histologic (preferred) or radiologic diagnosis of meningioma. All World Health Organization (WHO) grades (I, II and III) are allowed.\n2. All patients must have developed recurrent disease or progressive disease after receiving standard therapy (e.g., radiation or surgery) \\> 6 months ago or have been deemed ineligible to receive these therapies.\n3. Karnofsky Performance Status ≥ 50.\n4. Adequate hematologic function:\n\n   1. Absolute Neutrophil Count ≥ 1.5 × 10\\^9 \u002F L without granulocyte colony-stimulating factor support.\n   2. Platelet Count ≥ 100 × 10\\^9 \u002F L without transfusion.\n   3. Hemoglobin ≥ 9 g\u002FdL without transfusion within 7 days prior to screening assessment.\n5. Adequate renal function: ≥ 30 mL\u002Fmin according to the Cockcroft-Gault formula.\n6. Adequate hepatic function including:\n\n   1. Total bilirubin ≤ 1.5 × upper limit of normal (ULN).\n   2. Aspartate transaminase (AST) ≤ 3 × ULN without liver metastasis.\n   3. Alanine transaminase (ALT) ≤ 3 × ULN without liver metastasis.\n   4. AST or ALT ≤ 5 × ULN for patients with liver metastasis.\n   5. Patients with known Gilbert's syndrome may be included if total bilirubin ≤ 3 × ULN.\n7. Patients must have measurable disease by RANO meningioma criteria.\n8. Women of childbearing potential must have negative serum pregnancy testing at screening. All women will be considered childbearing potential unless meeting criteria including:\n\n   1. Achieved post-menopausal status as defined by cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have follicular stimulation hormone showing postmenopausal state. Women who have been amenorrhoeic for ≥ 12 months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anorexia, low body weight, ovarian suppression, anti-estrogen therapy or other medically inducible reasons.\n   2. Documented hysterectomy or bilateral oophorectomy surgery.\n   3. Medically confirmed ovarian failure.\n   4. Sexually active participants and their partners must agree to use medically accepted methods of contraception during the study and for 4 months after discontinuing study treatment.\n9. Recovery of baseline CTCAE v5.0 Grade ≤ 1 toxicity related to prior study treatments unless adverse events are clinically non-significant per investigator's discretion and\u002For stable on supportive therapy if needed.\n10. Patients must be willing and able to comply with trial protocol. This includes adhering to the treatment plan, scheduled visits, laboratory and other study procedures.\n11. Serum albumin ≥ 2.8 g\u002FdL.\n12. Prothrombin time (PT)\u002FInternational Normalized Ratio (INR) or partial thromboplastin time (PTT) test \\\u003C 1.3 × the laboratory ULN.\n\nExclusion Criteria\n\n1. Prior treatment with cabozantinib.\n2. Patients \\\u003C 18 years old.\n3. Patients who are pregnant or breast-feeding.\n4. 4\\. Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.\n5. Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.\n6. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) with 2 weeks before first dose of study treatment.\n7. Ejection fraction (EF) ≤ 50% by echocardiogram (ECHO). Multi-gated acquisition scan (MUGA) should be obtained to estimate EF if quality of ECHO is insufficient.\n8. Prior history of hypertensive encephalopathy at any time.\n9. History of congenital QT syndrome.\n10. Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms within 14 days of study registration. If initial QTcF is \\> 500 ms, two additional EKGs separated by at least 3 minutes should be performed, and if average of these consecutive results is QTcF is ≤ 500 ms, patient is eligible.\n11. Unstable cardiac arrhythmia within 6 months prior to study registration date.\n12. Urine Protein-to-Creatinine ratio (UPCR) \\>1 mg\u002Fmg or 24-hour urine protein \\> 1 gram.\n13. History of bleeding diathesis or significant unexplained coagulopathy (e.g., in the absence of anticoagulation).\n14. Clinical signs or symptoms of gastrointestinal obstruction requiring parenteral hydration, nutrition or feeding tube.\n15. Uncontrolled effusion management (pleural effusion, pericardial effusion or ascites) requiring recurrent drainage procedures.\n16. Active infection requiring parenteral antibiotic therapy.\n17. History of either positive hepatitis C virus (HCV) RNA viral load or detectable anti-HCV antibody; hepatitis B virus (HBV) infection with HBV surface antigen detection and\u002For positive HBV DNA viral load.\n18. Serious non-healing wound, ulcer, or bone fracture requiring intervention within 28 days prior to study registration date.\n19. Known hypersensitivity to cabozantinib or any component in formulation.\n20. Inability to swallow capsules, known intolerance to cabozantinib or its excipients, known malabsorption syndrome, or other conditions which impair intestinal absorption.\n21. Other severe acute or chronic medical conditions, which may increase study risk per treating investigator's discretion.\n22. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:\n\n    1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n    2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n23. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n    a. Cardiovascular disorders: i. Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.\n\n    ii. Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment.\n\n    iii. Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose of study treatment.\n\n    iv. Subjects with a diagnosis of incidental, sub-segmental PE or DVT within 6 months are allowed if stable, asymptomatic, and treated with a stable dose of permitted anticoagulation (see exclusion criterion #6) for at least 1 week before first dose of study treatment.\n\n    b. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: i. The subject has evidence of any concurrent malignancy invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n\n    ii. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment.\n\n    Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.\n24. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 mL) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n25. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease from another malignancy.\n26. Other clinically significant disorders that would preclude safe study participation.\n\n    1. Serious non-healing wound\u002Fulcer\u002Fbone fracture.\n    2. Uncompensated\u002Fsymptomatic hypothyroidism.\n    3. Moderate to severe hepatic impairment (Child-Pugh B or C).\n27. Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible",{"count":173,"type":20},24,[152],"A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma",[177],"Meningioma",[177,179,180,181],"central nervous system tumors","Recurrent meningioma","Progression meningioma",{"date":183,"type":32},"2026-05-14",{"date":185,"type":32},"2022-06-01",{"date":187,"type":20},"2028-05",{"name":38,"class":39},3,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":199,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":64},"100415393","phase-1-assess-use-of-18f-fluciclovine-for-patients-with-large-brain-metastases-treated-with-staged-stereotactic-radiosurgery-100415393","NCT04689048","Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery","Characterization of Large Brain Metastases With 18F-Fluciclovine PET\u002FCT Treated With Staged Stereotactic Radiosurgery","Inclusion Criteria:\n\n1. Male or female, age ≥18 years\n2. Performance status, Eastern Cooperative Oncology Group 0-2\n3. Confirmed diagnosis of brain metastases with at least one untreated lesion \\>2 cm in maximum diameter\n4. Plan for SSRS per the treating team\n5. For women of childbearing potential, a negative serum pregnancy test within 14 days of registration is required\n6. For females of reproductive potential: use of highly effective contraception for at least 4 weeks prior to screening and agreement to use such a method during study participation and for an additional 1 week after post-treatment 18F-fluciclovine positron emission tomography\u002Fcomputerized tomography\n\nExclusion Criteria:\n\n1. Prior anaphylactic reaction to 18F-fluciclovine\n2. Evidence of leptomeningeal disease\n3. Prior whole-brain radiation therapy\n4. Contraindication to MRI (e.g., due to safety reasons, such as presence of a pacemaker)\n5. Females pregnant at the expected time of 18F-fluciclovine administration\n6. Females who are expecting to be breastfeeding at the time of 18F-fluciclovine and unwilling to stop breast-feeding for 24 hours. Temporary cessation of breastfeeding 24 hours after the time of imaging is allowed\n7. Major medical illness or psychiatric\u002Fcognitive impairments, which in the investigator's opinion, will prevent completion of protocol therapy and\u002For preclude informed consent",{"count":198,"type":20},20,[101],"The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In addition, this study will look at the changes of the treated brain metastases using this imaging agent over time.",[105,104,106],[203,204,205,206,207],"brain","brain metastases","brain metastases, adult","brain cancer","Stereotactic Radiosurgery","2026-04-20",{"date":210,"type":32},"2026-04-22",{"date":212,"type":32},"2022-04-04",{"date":214,"type":20},"2027-12",{"name":38,"class":39},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":21,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":238,"locationsCount":64},"100631848","mucolock-for-treatment-of-stomatitis-100631848","NCT07506018","MucoLock™ for Treatment of Stomatitis","A Phase II Open-Label Trial of MucoLock™ Oral Rinse for the Treatment of Stomatitis Characterized by Oral Dysesthesia","Inclusion Criteria:\n\n* Age 18 years and older\n* Individuals with oral dysesthesia (worst VAS sensitivity\u002Fburning score ≥ 7 over the last week)\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Inability to comply with study instructions\n* Uncontrolled intercurrent illness or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\\*\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.\n* Advanced kidney disease\n* Patients receiving antineoplastic therapy \\[e.g., tyrosine kinase inhibitors (TKIs), radiation\\] that could increase the risk of oral dysesthesia\n* Known altered mental status, encephalopathy, or cognition impairment\n* Ataxia\n* Known alcohol use disorder\n* Concomitant opioid therapy\n* Diagnosis of oral cancer currently undergoing therapy\n* Already using topical therapy for mouth pain (e.g., lidocaine, Magic mouthwash)\\*\n* Any opioid pain medication\\*\n* Treatment with another investigational drug or other intervention within 2 weeks. Patients will be recommended to stop previous medication for 2 weeks before starting the study treatment.\n\n(asterisk) \\*Modifiable criteria, with a timeframe of 2 weeks for a washout period.",{"count":224,"type":20},25,[23],"The purpose of this research is to test how well people can tolerate MucoLock™ as a treatment for mouth pain or burning sensation and how well it works to reduce mouth pain or burning sensation. Study participants will be asked to use MucoLock™ topical solution as a \"swish and spit\" solution (similar to mouthwash) three times per day for 5 minutes each time, for 28 days.",[228,229,230,231,232],"Stomatitis","Pain","Burning Mouth","Burning Mouth Syndrome","Oral Dysesthesia","2026-04-16",{"date":208,"type":32},{"date":236,"type":32},"2026-04-15",{"date":187,"type":20},{"name":38,"class":39},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":246,"minAge":17,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":21,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":64},"100627902","phase-1-trastuzumab-deruxtecan--stereotactic-radiosurgery-srs-in-her2-breast-cancer-brain-metastases-100627902","NCT07454668","Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases","Phase 1 Trial of Trastuzumab Deruxtecan With Stereotactic Radiosurgery (SRS) in Participants With Brain Metastases From HER-2 Positive Breast Cancer","Inclusion Criteria:\n\n1. Histologically confirmed HER-2-positive breast cancer with newly diagnosed brain metastases.\n2. ECOG Performance Status (PS) of 0, 1, 2.\n3. Participants with 1-10 brain metastases will be candidates for T-DXd with SRS at the discretion of the treating radiation oncologist. Intra-cranial metastasis must measure 3 cm or less in the greatest dimension.\n4. Age ≥ 18 years\n5. Signed written informed consent by patient or legally authorized representative. A signed informed consent must be obtained prior to any study-specific procedures.\n6. Life expectancy of at least 12 weeks.\n7. Any number of prior systemic therapies will be allowed, except T-DXd.\n8. Hemoglobin ≥ 9 g\u002FdL, White blood count ≥ 3.0 × 109\u002FL, Absolute Neutrophil count ≥ 1.5 × 109\u002FL and platelet count ≥ 100 × 109\u002FL.\n9. Serum bilirubin ≤ 1.5 × upper limit of normal (ULN).\n10. AST and\u002For ALT ≤ 2 × ULN (≤ 5 × ULN when clearly attributable to the presence of liver metastases).\n11. Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance \\> 60 mL\u002Fmin.\n12. Ability to comply with study procedures and monitoring.\n13. For individuals of childbearing potential, a negative pregnancy test should be obtained within 7 days prior to the start of therapy.\n14. Participants must have left ventricular ejection fraction (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within 28 days before enrollment (to be assessed as clinically indicated).\n15. Male or female participants of reproductive potential need to employ two highly effective and acceptable forms of contraception throughout their participation in the study and for 7 months after last dose of T-DXd.\n\nHighly effective and acceptable forms of contraception are:\n\n* Male condom plus spermicide\n* Cap plus spermicide\n* Diaphragm plus spermicide\n* Copper T\n* Progesterone T\n* Levonorgestrel-releasing intrauterine system (e.g., Mirena®)\n* Implants\n* Hormone shot or injection\n* Combined pill\n* Mini-pill\n* Patch\n\nPostmenopausal individuals on the study (that will not need contraception) is defined as:\n\n* Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments.\n* LH and FSH levels in the postmenopausal range for individuals \\\u003C 50 years.\n* Radiation-induced oophorectomy with last menses \\> 1 year ago.\n* Chemotherapy-induced menopause with \\> 1 year interval since last menses.\n* Surgical sterilization (bilateral oophorectomy or hysterectomy).\n\nMen and women and members of all races and ethnic groups are eligible for this trial.\n\nExclusion Criteria:\n\n1. Participants with leptomeningeal metastases documented by MRI or CSF evaluation.\n2. Evidence of intra-tumoral or peri-tumoral hemorrhage deemed clinically significant by the treating physician.\n3. Brain metastases within 5 mm of the optic chiasm or optic nerve.\n4. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom, e.g., Crohn's disease, malabsorption, or CTCAE grade \\> 2 diarrhea of any etiology at baseline.\n5. History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, New York Heart Association (NYHA) functional classification of 3 or 4.\n6. Unable to undergo brain MRI.\n7. Screen for human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C. HIV\u002FHBV\u002FHCV testing per institutional practice.\n8. All toxicities from prior therapies must have resolved to CTCAE v5.0 grade 1 or better by the time of study enrollment.\n9. Other concurrent severe and\u002For uncontrolled concomitant medical conditions (e.g., active, or uncontrolled infection, uncontrolled diabetes, second active malignancy) that could cause unacceptable safety risks or compromise compliance with the protocol.\n10. Currently receiving other investigational cancer therapy (with the exception of continuing therapy with GnRH analogues) within 4 weeks prior to start of study treatment.\n11. Mean QT interval corrected heart rate (QTc) ≥ 470 ms calculated from 3 electrocardiograms using Fredericia's Correction, calculated as: 8.22 ∛(RR interval)\n12. LVEF \\\u003C50%.\n13. Ineligible for treatment with T-DXd.\n14. Ineligible for treatment with SRS.\n15. Active or prior documented ILD\u002Fpneumonitis or suspected ILD\u002Fpneumonitis that cannot be ruled out by imaging at screening.\n16. History of hypersensitivity to T-DXd.\n17. History and\u002For confirmed corneal ulceration.\n18. Pregnant or breast feeding. The patients should not breast feed for 7 months after stopping the drug.\n19. Use of anthracyclines will be prohibited while on the protocol.\n20. Prior cranial radiation is not allowed.","FEMALE",{"count":198,"type":20},[101],"A phase I clinical trial (a type of research study) for people with human epidermal growth factor receptor 2 (HER-2) positive breast cancer with metastasis to the brain. This research study will evaluate how well brain metastases can be controlled using a type of radiation therapy known as stereotactic radiosurgery (SRS) when combined with the therapeutic agent Trastuzumab Deruxtecan (T-DXd). The combined use of SRS with T-DXd is considered investigational.",[251,252,104,253,254],"Breast Cancer","HER2-positive Breast Cancer","Cancer","Cancer Metastatic","2026-03-02",{"date":257,"type":32},"2026-03-06",{"date":259,"type":20},"2026-06",{"date":261,"type":20},"2029-07",{"name":38,"class":39},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":21,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":64},"100491597","phase-2-zanubrutinib-with-pemetrexed-to-treat-relapsedrefractory-primary-and-secondary-central-nervous-system-cns-lymphomas-100491597","NCT05681195","Zanubrutinib With Pemetrexed to Treat Relapsed\u002FRefractory Primary and Secondary Central Nervous System (CNS) Lymphomas","Zanubrutinib With Pemetrexed for the Treatment of Relapsed\u002FRefractory Primary and Secondary CNS Lymphomas: A Phase II Trial With a Safety Lead-In","Inclusion Criteria:\n\n1. Any of the following diseases histologically confirmed:\n\n   1. Primary CNS lymphoma or isolated secondary CNS involvement by diffuse large B cell lymphoma with measurable disease\n   2. Cytologic diagnosis of B cell non-Hodgkin's lymphoma with measurable disease\n   3. Ocular lymphoma with histologic confirmation of ocular lymphoma and measurable intracranial tumor. Slit-lamp examination and vitreal or retinal biopsy will be done to confirm ocular lymphoma.\n2. Karnofsky performance status (KPS) ≥ 30% (≥ 50% for patients ≥ 60 years-old)\n3. Progressed during first-line chemotherapy and\u002For radiotherapy -OR- insufficient clinical response to previous therapy or relapsed after initial successful treatment OR unable to tolerate previous therapy defined as Grade 3+ acute kidney injury (AKI) and\u002For transaminase elevation according to CTCAE v 5.0 criteria preventing repeat treatment exposure OR prior glucarpidase use due to high dose methotrexate delayed clearance and\u002For toxicity OR those who would have been glucarpidase candidates due to delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered or toxic plasma methotrexate concentrations (\\>1 micromole per liter) in patients with delayed methotrexate clearance) due to impaired renal function OR unable to receive high dose methotrexate induction on every 2 week +\u002F- 3 days schedule due to deconditioning and\u002FOR need for physical rehabilitation between the high dose methotrexate treatments\n4. No systemic lymphoma by positron emission tomography (PET) CT or CT scan of the chest, abdomen, and pelvis with contrast\n5. Adequate bone marrow and organ function demonstrated by:\n\n   1. Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL\n   2. Platelets ≥ 75 x 10\\^9\u002FL and no platelet transfusion within the past 14 days prior to study enrollment\n   3. Hemoglobin (Hgb) ≥ 8 g\u002FdL and no red blood cell (RBC) transfusion within the past 14 days prior to study enrollment\n   4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal\n   5. Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome\n   6. Creatinine Clearance (CrCl)\\> 45 mL\u002Fminute using Cockcroft-Gault formula\n6. Ability to understand and sign written informed consent prior to study entry unless the subject suffers from cognitive or physical impairment due to their CNS malignancy or due to a known underlying medical condition in which case consent could be signed by proxy\n7. Life expectancy of at least 2 months\n8. Females of childbearing potential must use highly effective method of contraception for the duration of the study and ≥ 30 days after the last dose of zanubrutinib. Female must also have a negative urine or serum pregnancy test ≤ 7 days before initial treatment.\n\n   * The investigator or a designated associate is requested to advise the patients how to achieve highly effective birth control (failure rate of less than 1%), e.g., intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner and sexual abstinence. Females using hormonal contraception should use barrier methods in addition.\n   * Male patients with a female partner of childbearing potential are eligible if abstinent, vasectomized, or if they agree to the use of barrier contraception with other methods described above during the study treatment period and for up to one week after the last dose of zanubrutinib.\n\n   Agreement to use contraception during study participation\n   * Female patients of childbearing potential must practice highly effective methods of contraception.\n   * Male patients with female partners must be abstinent, vasectomized, or agree to the use of barrier contraception in combination with other methods. Acceptable contraception methods are included in the study protocol.\n   * Patients using hormonal contraceptives (e.g., birth control pills or devices) must use a barrier method of contraception (e.g., condoms) as well.\n9. For patients with Infectious disease, must have:\n\n   1. HIV positive with negative viral load and CD4 count \\> 400\n   2. Non-viremic Hepatitis C Virus (HCV)\n   3. HBcAb (Hepatitis B core positive) and HBsAg negative\n\nExclusion Criteria:\n\n1. Serious uncontrolled concurrent illness or comorbid condition\n2. Other active systemic malignancy except for basal cell carcinoma of the skin, cervical carcinoma in situ or very low and low risk prostate cancer under observation. Patients with a remote history (3 years or more) of malignancy are eligible for the protocol in the absence of active disease\n3. Concurrent chronic systemic immune therapy, targeted therapy not indicated in this study protocol\n4. Unable to comprehend the study requirements or who are not likely to comply with the study protocol\n5. Prior participation in chemotherapy, cytotoxic therapy, immunotherapy, radiation therapy or therapeutic protocols within 2 weeks of protocol treatment\n6. Pregnant (confirmed by serum or urine β-HCG) or lactating\n7. Transaminases \\> 3 times above the upper limits of the institutional normal\n8. Patients must not have pre-existing immunosuppression, concurrent immunosuppressive treatment with the exception of dexamethasone, or low dose prednisone with a total dose equivalent to 15 mg of prednisone a day or less for chronic conditions. Allogeneic stem cell transplant recipients as well as other organ transplant recipients are excluded. Autologous stem cell transplant recipients will qualify if relapse occurs at one year after the stem cell transplantation. Short course of dexamethasone up to 40 mg orally or intravenously daily with or without taper for CNS lymphoma symptom control is allowed.\n9. Patients should not have active and\u002For ongoing autoimmune anemia and\u002For autoimmune thrombocytopenia (e.g., idiopathic thrombocytopenia purpura).\n10. Non-healing wound, ulcer or bone fracture\n11. Known bleeding diathesis (e.g., von Willebrand's disease) or hemophilia\n12. Cerebrovascular accident or intracranial hemorrhage within 6 months of the study treatment; arterial or venous thrombotic or embolic event such as deep vein thrombosis or pulmonary embolism within 3 months before the start of study treatment. Patients with upper extremity catheter-related deep venous thrombosis will not be excluded.\n13. Concurrent use of warfarin or other vitamin K antagonists (need to be stopped 7 days prior to starting on trial drug)\n14. Infectious disease: HIV positive patients with positive viral load and CD4+ count \\\u003C 400 are excluded. HIV patients must have established and consistent infectious disease specialist care. HIV positive patients have to agree for every 12-week monitoring of viral load. Patients with the emergence of HIV viral load on the trial treatment will be referred to the infectious disease specialist and can continue on the trial treatment unless recommended to stop by the infectious disease specialist and PI. If the viral load reaches 100,000 copies per milliliter or above, the patient would be referred to an infectious disease specialist for and evaluation and would be taken off the trial.\n15. Patients with presence of HCV antibody are eligible if HCV RNA is undetectable and if they are willing to undergo monitoring for HCV reactivation every 12 weeks. HCV patients will be taken off trial if there is 1 log increase in viral load after the initial detection of HCV viral load regardless of liver function tests (LFTs). Patients will be referred promptly to hepatology specialist with the first detectable viral load.\n16. Patients with detectable hepatitis B surface antigen (HBsAg) are excluded. Patients with viral hepatitis B core antibody (HBcAb) positivity, but absence of HBsAg, are eligible if HBV DNA is undetectable and if they are willing to undergo monitoring for Hepatitis B Virus (HBV) reactivation every 12 weeks. HBV patients will be taken off trial if there is 1 log increase in viral load after the initial detection of HBV viral load regardless of LFTs. Patients will be referred promptly to hepatology specialist with the first detectable viral load.\n17. Currently active, clinically significant cardiovascular disease including the following:\n\n    1. Myocardial infarction within 6 months before screening\n    2. Unstable angina within 3 months before screening\n    3. New York Heart Association class III or IV congestive heart failure\n    4. History of clinically significant arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes)\n18. Any uncontrolled active systemic infection or infection requiring systemic treatment that was completed ≤ 7 days before the first dose of therapy\n19. Participants who received a strong cytochrome P450 (CYP) 3A inhibitor or inducer within 7 days prior to the first dose of protocol anti-fungal prophylaxis, or participants who require continuous treatment with a strong CYP3A inhibitor\u002Finducer (i.e., except for any medication to be specifically mentioned in this protocol)\n20. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the patient's safety, or put the study at undue risk. Participants with suspicious radiologic evidence of aspergillosis infection (i.e., chest CT and\u002For brain MRI) will not be eligible unless confirmatory laboratory testing of Beta-D glucan and aspergillus antigen are negative\n21. Prior treatment with pemetrexed or a Bruton's tyrosine kinase (BTK) inhibitor for lymphoma\n22. Vaccination with a live or attenuates vaccine within 28 days prior to the first dose of zanubrutinib. Live or attenuated vaccines are not allowed during treatment with zanubrutinib\n23. Hypersensitivity to zanubrutinib or pemetrexed or any of the other ingredients of the applicable study drug",{"count":271,"type":20},15,[152],"This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people who have relapsed or refractory (RR) primary central nervous system lymphoma (PCNSL) or isolated central nervous system relapse of B cell lymphoma (SCNSL). Assessments include how well people respond to this treatment, whether their disease gets better or worse, and their survival. Safety of this treatment and its side effects also will be assessed.",[275,276,277,278],"Primary Central Nervous System Lymphoma","Secondary Central Nervous System Lymphoma","Relapsed Cancer","Refractory Cancer",{"date":280,"type":32},"2026-03-03",{"date":282,"type":32},"2024-04-25",{"date":284,"type":20},"2033-02",{"name":38,"class":39},{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":21,"phases":296,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":64},"100480310","phase-1-prophylactic-radiotherapy-of-minimally-symptomatic-spinal-disease-100480310","NCT05534321","Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease","Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease (PROMISSeD Trial)","PROMISSeD","Inclusion Criteria:\n\n1. Histologically-confirmed solid tumor malignancy with greater than 5 sites of metastatic disease detected on cross-sectional imaging.\n2. Has high-risk bone metastases that are asymptomatic or minimally symptomatic (not requiring opioids). High risk metastases are defined as:\n\n   1. Bulkiest sites of spinal osseous disease ≥ 2cm,\n   2. Disease at junctional levels, including the thoracic apex (Occiput to C2, C7-T1, T12-L2, and L5- S1)\n   3. Disease with posterior element involvement, including interspinous, unilateral, or bilateral facet joints.\n   4. Vertebral body compression deformity \\> 50%.\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.\n4. Age ≥ 18 years.\n5. Able to provide informed consent.\n6. Patients at reproductive potential must agree to practice an effective contraceptive method. Women of childbearing potential must not be pregnant or lactating.\n\nExclusion Criteria:\n\n1. Previous RT to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.\n2. Serious medical co-morbidities precluding RT.\n3. Pregnant or lactating women.\n4. Target lesion(s) is\u002Fare complicated bone metastases that include clinical or radiological evidence of spinal cord compression or impending pathological fracture.\n5. Leptomeningeal disease.\n6. Patients whose entry to the trial will cause unacceptable clinical delays in their planned management.",{"count":295,"type":20},74,[101,152],"Early palliative care has been shown to improve the quality of life and even survival for patients with metastatic cancer. More and more supportive oncology teams in cancer centers now advocate for early integration of radiation therapy (RT) in a patient's palliative management course. While multiple randomized studies have evaluated the efficacy of different RT regimens in the treatment of symptomatic bone lesions, few studies have examined the impact of early, upfront RT for asymptomatic or minimally symptomatic (non- opioid dependent) spine metastases and its efficacy in preventing skeletal-related events (SREs). Since the pathophysiology of spinal metastatic disease is distinct from other bony metastatic disease, the proposed trial seeks to understand whether it is beneficial to patients with minimally symptomatic disease to undergo upfront RT to reduce the risks of SREs and their sequelae, including hospitalizations.",[299],"Spine Metastases",[301,302,303,304],"Radiotherapy (RT)","Palliative radiotherapy","High-risk asymptomatic spine metastases","Minimal asymptomatic spine metastases","2026-02-13",{"date":307,"type":32},"2026-02-17",{"date":309,"type":32},"2022-08-29",{"date":311,"type":20},"2027-09",{"name":38,"class":39},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":322,"conditions":323,"keywords":327,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":64},"100497418","improving-understanding-of-glioblastoma-through-preservation-of-biologically-active-brain-tissue-100497418","NCT05756985","Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue","Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue (PRESERVE GBM)","Inclusion Criteria:\n\n1. Have the appearance of high-grade glioma on magnetic resonance (MR) imaging if allowed to consent and will undergo the procedure if the frozen is consistent with glioblastoma or gliosarcoma OR Patients with a history of histologically confirmed diagnosis of World Health Organization Grade glioblastoma or gliosarcoma that are undergoing repeat resection of a recurrent tumor as identified on preoperative MR imaging\n2. Aged ≥ 18 years old\n3. Contrast-enhancing tumor volume of at least 10 cc on the preoperative, volumetric MRI within 1 month prior to surgery\n4. Provision of signed and dated informed consent form by participant or legally authorized representative (LAR), if applicable\n\nExclusion Criteria:\n\n1\\. Has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the results of the study or is not in the best interest of the participant, in the opinion of the treating investigator.",{"count":321,"type":20},120,"To collect and preserve glioblastoma tissue during standard of care tumor resection surgery and blood for future molecular and genetic testing. Tissue for research will be collected from three different regions within the same tumor to study how these regions differ in their structure, DNA, and RNA and also to compare the data obtained from this testing to imaging data found in the medical record. The goal of this study is to help us better understand what the glioblastoma tumor tissue looks like and how it functions. This understanding can lead to new therapies for the treatment of glioblastoma in the future.",[324,325,326],"Glioblastoma","Glioblastoma Multiforme","Gliosarcoma",[328],"specimen banking","2026-02-02",{"date":331,"type":32},"2026-02-04",{"date":333,"type":32},"2024-12-11",{"date":335,"type":20},"2029-01",{"name":38,"class":39},{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":21,"phases":346,"briefSummary":347,"conditions":348,"keywords":352,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":64},"100491480","stereotactic-body-radiation-and-tumor-treating-fields-for-locally-advanced-pancreas-cancer-100491480","NCT05679674","Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer","Phase 2 Trial of Ablative MRI-guided Stereotactic Body Radiation Therapy and Tumor Treating Fields for Locally Advanced Pancreas Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced adenocarcinoma of the pancreas. Locally advanced pancreas cancer as per National Comprehensive Cancer Network (NCCN) Guidelines.\n* Regional lymph node involvement is permitted if able to be treated with radiation therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* At least 3 months of prior FOLFIRINOX, modified FOLFIRINOX, and\u002For gemcitabine\u002Fnab-paclitaxel delivered for pancreas cancer without evidence of distant progression on restaging radiographic studies.\n* Carbohydrate antigen 19-9 (CA 19-9) ≤500 U\u002FmL on most recent assessment prior to study enrollment.\n* Adequate normal organ and marrow function as defined below:\n\n  i. Hemoglobin ≥8.0 g\u002FdL that may be achieved with transfusion ii. Absolute neutrophil count (ANC) ≥1500 per mm\\^3 iii. Platelet count ≥60,000 per mm\\^3 iv. Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN) v. AST (SGOT)\u002FALT (SGPT) ≤3 x institutional ULN\n* People of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a participant become pregnant or suspect they are pregnant while participating in this study, they must inform the treating physician immediately.\n* Able to operate the tumor treating field (NovoTTF-100L) system independently or with assistance.\n* All participants must sign written informed consent.\n\nExclusion Criteria:\n\n* Distant metastasis from pancreas cancer.\n* Contraindication to having a magnetic resonance imaging (MRI) scan.\n* Prior abdominal radiation therapy.\n* History of any primary malignancy with the exception of:\n\n  1. Malignancy treated with curative intent and with no known active disease for at least 3 years before enrollment on this study.\n  2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  3. Adequately treated carcinoma in situ without evidence of disease (i.e., cervical carcinoma in situ; superficial bladder cancer).\n* Any unresolved toxicity (Common Terminology Criteria for Adverse Events version 5.0 \\> grade 2) from previous anti-cancer therapy. Participants with irreversible toxicity that is not reasonably expected to worsen by treatment on this study are permitted to enroll on this study.\n* History of inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis).\n* Any condition in the opinion of the investigator that would interfere with evaluation of study treatment or interpretation of patient safety or study results.\n* Participants who are pregnant or breastfeeding. Patients with an electrical implantable device in the torso. Examples of electrical implanted medical devices include spinal cord stimulators, vagus nerve stimulators, pacemakers, and defibrillators.\n* History of significant uncontrolled cardiovascular disease. Significant cardiac disease includes second\u002Fthird degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse.\n* History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial.\n* Known allergy to medical adhesives or conductive hydrogel \\[gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes\\].",{"count":345,"type":20},48,[23],"The purpose of this clinical trial is to determine whether using chemotherapy followed by stereotactic ablative body radiation therapy (SABR) and tumor treating fields (TTF) will slow tumor growth in people with locally advanced pancreas cancer. All participants will receive SABR therapy once per day for five days and use the TTF system for at least 18 hours per day starting on the first day of SABR until the tumor progresses or severe toxicity develops.",[349,350,351],"Pancreas Cancer","Locally Advanced","Locally Advanced Pancreatic Adenocarcinoma",[353,354,355],"tumor treating fields","stereotactic ablative body radiation","chemotherapy","2026-01-08",{"date":358,"type":32},"2026-01-12",{"date":360,"type":32},"2023-09-21",{"date":362,"type":20},"2027-06",{"name":38,"class":39},{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":21,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":64},"100592259","phase-2-ruxolitinib-with-radiation-and-temozolomide-compared-to-radiation-and-temozolomide-for-newly-diagnosed-glioblastoma-100592259","NCT06991101","Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma","Randomized Phase 2 Trial of Ruxolitinib in Combination With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma.","Inclusion Criteria:\n\n1. Provision of signed informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Individuals of any sex, gender, race, or ethnicity ≥ 18 years of age.\n4. Histologically confirmed glioblastoma as defined by the World Health Organization (WHO) 2021 Criteria (IDH-wildtype) that is either methylated, unmethylated, or indeterminate MGMT.\n5. Confirmation that patient has sufficient tissue to undergo MGMT and IDH testing, as mandated.\n6. Must have a Karnofsky performance status (KPS) ≥ 70% (i.e., the patient must be able to care for themself with occasional help from others).\n7. Adequate organ (liver and renal) and bone marrow function within 14 days before randomization. For all parameters listed below, the most recent results available must be used:\n\n   1. Absolute neutrophil count (ANC) ≥ 1500\u002Fmm3. Note: Granulocyte-colony stimulating factor (G-CSF) administration is not allowed within 1 week prior to screening assessment.\n   2. Platelet count ≥ 100,000\u002Fmm3. Note: Platelet transfusion is not allowed within 1 week prior to registration.\n   3. Total bilirubin (TBL) ≤ 1.5 × institutional upper limit of normal (ULN).\n   4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN.\n   5. Serum albumin ≥ 2.5 g\u002FdL.\n8. Patients able to become pregnant: use of highly effective contraception for at least one (1) month prior to screening and agreement to use such a method. Should a participant become pregnant or suspect that they are pregnant while participating in this study, they should notify the treating physician immediately. Such individuals must have a negative pregnancy test.\n9. Patients must have no concurrent malignancy except curatively treated early-stage bladder and prostate cancer that has been completed resected, basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast, adequately treated stage I or II cancer from which the patient is in complete remission. Patients with other prior malignancies must be disease-free for ≥ 3 years.\n\nExclusion Criteria:\n\n1. Patients who are pregnant or breast-feeding. The anti-proliferative activity of this experimental drug and temozolomide may be harmful to the developing fetus or nursing infant.\n2. Patients receiving concurrent therapy for their brain tumor (e.g., chemotherapeutics or investigational agents).\n3. Patients with a concurrent or prior malignancy are ineligible unless they are patients with curatively treated carcinoma-in-situ or basal cell carcinoma of the skin. Patients who have been free of disease (any prior malignancy) for at least 3 years are eligible for this study.\n4. Patients who have had repeat craniotomy for tumor therapy after receiving radiation therapy and temozolomide treatment.\n5. Patients who received other chemotherapeutics or investigational agents in addition to their radiation therapy and concomitant temozolomide treatment.\n6. Patient has previously taken ruxolitinib or is allergic to components of the study drug.\n7. Patients using warfarin.\n8. Uncontrolled immunodeficiency virus infection or active tuberculosis.\n9. Patients with active serious infections requiring systemic therapy.\n10. Known Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment or at risk for HBV reactivation. At risk for HBV reactivation is defined as hepatitis B surface antigen positive or anti-hepatitis B core antibody positive. Participants with previous positive serology results must have negative polymerase chain reaction results.\n11. Patient has significant abnormalities on screening electrocardiogram (EKG) and active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, New York Heart Association (NYHA) Grade ≥2 heart failure, uncontrolled hypertension, valvular disease, pericarditis, myocardial infarction, or other thrombosis events like including pulmonary embolism or deep vein thrombosis within 6 months of screening.\n12. Any other serious medical\u002Fpsychiatric condition, in the judgement of the investigator, that likely to interfere or limit compliance with study requirements\u002Ftreatment.",{"count":372,"type":20},190,[152],"The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to take the study drug ruxolitinib in addition to the standard of care temozolomide and radiation therapy and the other half will be assigned to the standard of care temozolomide and radiation therapy only. This assignment will be randomized in a 1-to-1 ratio, like the flip of a coin.",[324,106,325,376,377,378,379],"Glioblastoma Multiforme of Brain","Glioblastoma Multiforme, Adult","MGMT-Unmethylated Glioblastoma","MGMT-Methylated Glioblastoma","2025-12-23",{"date":382,"type":32},"2025-12-26",{"date":384,"type":32},"2025-12-03",{"date":386,"type":20},"2030-12",{"name":38,"class":39},{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":21,"phases":396,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":64},"100481844","phase-2-characterization-of-18f-fluciclovine-pet-amino-acid-radiotracer-in-resected-brain-metastasis-100481844","NCT05554302","Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis","CONCORDANT","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Performance status, Eastern Cooperative Oncology Group (ECOG) 0-3\n3. Radiographic diagnosis of brain metastasis\n4. Patient planned for surgical intervention for at least 1 metastasis\n5. Patient planned for postoperative SRS\n\nMale or female patients of reproductive potential need to employ two highly effective and acceptable forms of contraception for at least 4 weeks prior to screening and agreement to use such a method during study participation and for an additional 1 week after post-treatment 18F-Fluciclovine PET\u002FCT. Highly effective and acceptable forms of contraception are:\n\n* Male condom plus spermicide\n* Cap plus spermicide\n* Diaphragm plus spermicide\n* Copper T\n* Progesterone T\n* Levonorgestrel-releasing intrauterine system (e.g., Mirena®)\n* Implants\n* Hormone shot or injection\n* Combined pill\n* Mini-pill\n* Patch\n\nPostmenopausal people on the study (that will not need contraception) is defined as at least one of the following:\n\n* Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments\n* Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the postmenopausal range for women under 50\n* Radiation-induced oophorectomy with last menses \\> 1 year ago\n* Chemotherapy-induced menopause with \\>1 year interval since last menses\n* Surgical sterilization (bilateral oophorectomy or hysterectomy).\n\nExclusion Criteria:\n\n1. Prior anaphylactic reaction to 18F-Fluciclovine\n2. Evidence of leptomeningeal disease\n3. Prior whole-brain radiation therapy\n4. Contraindication to MRI (e.g., due to safety reasons, such as presence of a pacemaker)\n5. Pregnant at the expected time of 18F-fluciclovine administration\n6. Expecting to be breastfeeding at the time of 18F-Fluciclovine and unwilling to stop breast-feeding for 24 hours. Temporary cessation of breastfeeding 24 hours after the time of imaging is allowed.",{"count":198,"type":20},[152],"This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET\u002FCT scan. The goal of the study is to determine whether a specific imaging agent, known as 18F-Fluciclovine, will help physicians evaluate the extent of surgery and determine if there is any visible tumor above what MRI alone can identify as well as improve the physicians' ability to detect recurring disease. This agent (18F-Fluciclovine) is investigational for the imaging of brain metastases.",[104,106],[400,401,402],"Brain metastases","Brain cancer","Stereotactic radiosurgery","2025-11-26",{"date":405,"type":32},"2025-12-01",{"date":407,"type":32},"2023-01-10",{"date":409,"type":20},"2030-01",{"name":38,"class":39},{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":21,"phases":421,"briefSummary":422,"conditions":423,"keywords":425,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":64},"100424108","dose-escalated-spine-sbrt-for-localized-metastasis-to-the-spinal-column-100424108","NCT04802603","Dose-Escalated Spine SbRT for Localized Metastasis to the Spinal Column","Dose-Escalated Spine SbRT (DESSRT) for Localized Metastasis to the Spinal Column","DESSRT","Inclusion Criteria:\n\n* Zubrod Performance Status 0-2\n* Localized spine metastasis from a solid tumor from the C1 to L5 levels (a solitary spine metastasis, two separate spine levels, or up to 3 separate sites; each of the separate sites may have a maximal involvement of 2 contiguous vertebral bodies)\n* Patients with epidural extension are eligible as long as there is a ≥ 2 mm gap between the spinal cord and the edge of the epidural lesion\n* Paraspinal disease extension is allowed as long as it measures ≤ 5 cm in the greatest dimension and that it is contiguous with the spine metastasis\n* For patients enrolled in cohort 2, the minimum time to re-irradiation should be 6 months\n* Numerical Rating Pain Scale (NRPS) score of ≥ 5 at the index site(s) (as rated when the patient is not taking pain medication)\n\nExclusion Criteria:\n\n* Radiosensitive histologies (myeloma, lymphoma, germ cell tumors, small cell lung cancer)\n* Non-ambulatory patients\n* \\>50% loss of vertebral body height or spinal instability to due pathologic compression fracture\n* Frank spinal cord compression, spinal cord displacement, or epidural extension within 2 mm of the spinal cord\n* Rapid neurologic decline\n* Patients for whom an MRI of the spine is medically contraindicated\n* Pregnant women",{"count":420,"type":20},60,[23],"This study is being done to determine the feasibility and tolerability of a novel regimen of spine stereotactic radiosurgery (SSRS). SSRS delivers high doses of radiation to tumors of the spine using precision techniques.\n\nIn standard medical care, conventional SSRS is delivered in only 1 or 2 treatments. When this treatment is delivered in only 1-2 treatments, a high dose is used which can increase the side effects of treatment. This study aims to test an alternative technique of delivering SSRS over 5 treatments. By delivering the radiation therapy over multiple treatments, the dose of radiation is less per treatment.",[299,424],"Metastasis Spine",[426,427],"Localized Metastasis","Spinal Column","2025-11-13",{"date":430,"type":32},"2025-11-14",{"date":432,"type":32},"2021-03-14",{"date":434,"type":20},"2029-12-31",{"name":38,"class":39},""]